The invention is about a potential therapeutic approach for cancers. The exosomes derived from Vδ2-T cellsnot only directly kill tumor cells but also indirectly inhibit tumor development and progression by enhancing T cell–mediated antitumor activities, which offers great possibility to overcome the shortcomings of conventional immunotherapies for tumors as a cell-free therapy.
Current treatment options for EBV-associated cancers are very limited with remarkable unwanted off-target toxicities and incompletely effective for relapsed or refractory diseases. Novel cell-based immunotherapy may be able to inhibit tumor growth; however, could be seriously impeded due to the immunosuppressive tumor microenvironment, and may also create safety issues.
Founded in 1911, The University of Hong Kong (HKU) is the first and oldest institution of higher education in Hong Kong. For over a century, the University has dedicated itself to creating knowledge, providing education, and serving society. Today, HKU has an established worldwide reputation for being a research-led comprehensive University with ten Faculties and a strong commitment to intellectual freedom, liberty and diversity. HKU has a proud record of academic recognition in researches through honours and awards received from both local and international bodies.